Interleukin-21 Influences Glioblastoma Course: Biological Mechanisms and Therapeutic Potential

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2023 Sep 28

PMID 37759505

Authors

Alberto Repici

Alessio Ardizzone

Alessia Filippone

Cristina Colarossi

Marzia Mare

Gabriele Raciti

Deborah Mannino

Salvatore Cuzzocrea

Irene Paterniti

Emanuela Esposito

Affiliations

Soon will be listed here.

Abstract

Brain tumors represent a heterogeneous group of neoplasms involving the brain or nearby tissues, affecting populations of all ages with a high incidence worldwide. Among the primary brain tumors, the most aggressive and also the most common is glioblastoma (GB), a type of glioma that falls into the category of IV-grade astrocytoma. GB often leads to death within a few months after diagnosis, even if the patient is treated with available therapies; for this reason, it is important to continue to discover new therapeutic approaches to allow for a better survival rate of these patients. Immunotherapy, today, seems to be one of the most innovative types of treatment, based on the ability of the immune system to counteract various pathologies, including cancer. In this context, interleukin 21 (IL-21), a type I cytokine produced by natural killer (NK) cells and CD4 T lymphocytes, appears to be a valid target for new therapies since this cytokine is involved in the activation of innate and adaptive immunity. To match this purpose, our review deeply evaluated how IL-21 could influence the progression of GB, analyzing its main biological processes and mechanisms while evaluating the potential use of the latest available therapies.

Citing Articles

The mechanism of cytokine regulation of cancer occurrence and development in the tumor microenvironment and its application in cancer treatment: a narrative review.

Qu R, Zhao Y, Zhang Y Transl Cancer Res. 2024; 13(10):5649-5663.

PMID: 39525000 PMC: 11543031. DOI: 10.21037/tcr-24-679.

Signaling Pathways of AXL Receptor Tyrosine Kinase Contribute to the Pathogenetic Mechanisms of Glioblastoma.

Repici A, Ardizzone A, Luca F, Colarossi L, Prestifilippo A, Pizzino G Cells. 2024; 13(4.

PMID: 38391974 PMC: 10886920. DOI: 10.3390/cells13040361.

References

Davis I, Brady B, Kefford R, Millward M, Cebon J, Skrumsager B . Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res. 2009; 15(6):2123-9. DOI: 10.1158/1078-0432.CCR-08-2663. View

Guven-Maiorov E, Acuner-Ozbabacan S, Keskin O, Gursoy A, Nussinov R . Structural pathways of cytokines may illuminate their roles in regulation of cancer development and immunotherapy. Cancers (Basel). 2014; 6(2):663-83. PMC: 4074797. DOI: 10.3390/cancers6020663. View

Gowda A, Roda J, Hussain S, Ramanunni A, Joshi T, Schmidt S . IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood. 2008; 111(9):4723-30. PMC: 2343602. DOI: 10.1182/blood-2007-07-099531. View

Ardizzone A, Calabrese G, Campolo M, Filippone A, Giuffrida D, Esposito F . Role of miRNA-19a in Cancer Diagnosis and Poor Prognosis. Int J Mol Sci. 2021; 22(9). PMC: 8125123. DOI: 10.3390/ijms22094697. View

Spolski R, Kashyap M, Robinson C, Yu Z, Leonard W . IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc Natl Acad Sci U S A. 2008; 105(37):14028-33. PMC: 2544573. DOI: 10.1073/pnas.0804358105. View

Sun Y, Zhang Z, Zhang C, Zhang N, Wang P, Chu Y . An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition. Mol Ther Oncolytics. 2022; 26:105-119. PMC: 9233193. DOI: 10.1016/j.omto.2022.05.008. View

Joalland N, Chauvin C, Oliver L, Vallette F, Pecqueur C, Jarry U . IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors. J Immunother. 2018; 41(5):224-231. DOI: 10.1097/CJI.0000000000000225. View

Rasmussen T, Andersen T, Hvid M, Hetland M, Horslev-Petersen K, Stengaard-Pedersen K . Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol. 2010; 37(10):2014-20. DOI: 10.3899/jrheum.100259. View

Kitamura Y, Toda M . [Medical Treatments for Malignant Brain Tumor]. Brain Nerve. 2023; 75(5):561-566. DOI: 10.11477/mf.1416202379. View

10.

Louveau A, Harris T, Kipnis J . Revisiting the Mechanisms of CNS Immune Privilege. Trends Immunol. 2015; 36(10):569-577. PMC: 4593064. DOI: 10.1016/j.it.2015.08.006. View

11.

Thakkar J, Dolecek T, Horbinski C, Ostrom Q, Lightner D, Barnholtz-Sloan J . Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014; 23(10):1985-96. PMC: 4185005. DOI: 10.1158/1055-9965.EPI-14-0275. View

12.

Kasaian M, Whitters M, Carter L, Lowe L, Jussif J, Deng B . IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity. 2002; 16(4):559-69. DOI: 10.1016/s1074-7613(02)00295-9. View

13.

Holland E . Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A. 2000; 97(12):6242-4. PMC: 33993. DOI: 10.1073/pnas.97.12.6242. View

14.

Lim M, Xia Y, Bettegowda C, Weller M . Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018; 15(7):422-442. DOI: 10.1038/s41571-018-0003-5. View

15.

Ha H, Lim J . Managing Side Effects of Cytotoxic Chemotherapy in Patients With High Grade Gliomas. Brain Tumor Res Treat. 2022; 10(3):158-163. PMC: 9353159. DOI: 10.14791/btrt.2022.0018. View

16.

Tilg H, Trehu E, Atkins M, Dinarello C, Mier J . Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994; 83(1):113-8. View

17.

Mattiuzzi C, Lippi G . Current Cancer Epidemiology. J Epidemiol Glob Health. 2019; 9(4):217-222. PMC: 7310786. DOI: 10.2991/jegh.k.191008.001. View

18.

Perkins A, Liu G . Primary Brain Tumors in Adults: Diagnosis and Treatment. Am Fam Physician. 2016; 93(3):211-7. View

19.

Pulliam S, Uzhachenko R, Adunyah S, Shanker A . Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett. 2015; 169:61-72. PMC: 4710466. DOI: 10.1016/j.imlet.2015.11.007. View

20.

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View